PMID: 6894266Nov 1, 1980Paper

Studies on heart. XIX. Isolation of an atrial peptide that improves the rhythmicity of cultured myocardial cell clusters

Chemical & Pharmaceutical Bulletin
S AonumaT Makino

Abstract

No abstract listed.

Citations

Antiarrhythmic peptide has no direct cardiac actions

Aug 15, 1989·Experientia·T ArgentieriJ R Wiggins

Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptides.

Nov 28, 2009·Naunyn-Schmiedeberg's Archives of Pharmacology·Stefan DheinFriedrich-Wilhelm Mohr

Increasing gap junctional coupling: a tool for dissecting the role of gap junctions

Jun 15, 2007·The Journal of Membrane Biology·Lene Nygaard AxelsenMorten Schak Nielsen

New drugs for atrial fibrillation.

Jun 7, 2008·Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing·Matthias HammwöhnerAndreas Goette

Increase in gap junction conductance by an antiarrhythmic peptide

May 26, 1997·European Journal of Pharmacology·A MüllerS Dhein

Gap junction channels in the cardiovascular system: pharmacological and physiological modulation

Jul 17, 1998·Trends in Pharmacological Sciences·S Dhein

Peptides acting at gap junctions

Sep 10, 2002·Peptides·Stefan Dhein

Pharmacological modulation and differential regulation of the cardiac gap junction proteins connexin 43 and connexin 40

Feb 5, 2003·Biology of the Cell·Stefan DheinJaques Antoine Haefliger

Dysregulation of cell adhesion proteins and cardiac arrhythmogenesis

Apr 6, 2006·Clinical Medicine & Research·Jifen LiGlenn L Radice

Cardiac to cancer: connecting connexins to clinical opportunity

Mar 13, 2014·FEBS Letters·Christina L GrekGautam S Ghatnekar

Protein kinase Calpha mediates the effect of antiarrhythmic peptide on gap junction conductance

Jun 18, 2002·Cell Communication & Adhesion·S DheinL Polontchouk

Rotigaptide (ZP123) reverts established atrial conduction velocity slowing

Mar 15, 2006·Cell Communication & Adhesion·Ketil HauganJørgen Søberg Petersen

Atrial selectivity of antiarrhythmic drugs.

Jun 5, 2013·The Journal of Physiology·Ursula RavensMichael Knaut

Antiarrhythmic therapy in atrial fibrillation

Jul 14, 2010·Pharmacology & Therapeutics·Ursula Ravens

Prevention of ischemia-induced reentrant ventricular arrhythmias by a peptide that enhances gap junctional conductance

Jun 5, 2003·Journal of Cardiovascular Electrophysiology·Steven M Pogwizd

ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs

Jun 5, 2003·Journal of Cardiovascular Electrophysiology·Dezhi XingJames B Martins

Pharmacological modulation of connexin-formed channels in cardiac pathophysiology

Jan 27, 2011·British Journal of Pharmacology·Elke De VuystLuc Leybaert

Pharmacology of gap junctions. New pharmacological targets for treatment of arrhythmia, seizure and cancer?

Oct 12, 2005·Biochimica Et Biophysica Acta·Aida Salameh, Stefan Dhein

Connexins in the heart.

Nov 2, 2014·Cell and Tissue Research·Pier D Lambiase, Andrew Tinker

The antiarrhythmic peptide analog ZP123 prevents atrial conduction slowing during metabolic stress

May 10, 2005·Journal of Cardiovascular Electrophysiology·Ketil HauganMorten Schak Nielsen

Treatment with the gap junction modifier rotigaptide (ZP123) reduces infarct size in rats with chronic myocardial infarction

Feb 24, 2006·Journal of Cardiovascular Pharmacology·Ketil HauganJørgen Søberg Petersen

Innovative approaches to anti-arrhythmic drug therapy

Dec 2, 2006·Nature Reviews. Drug Discovery·Stanley Nattel, Leif Carlsson

Effect of ZP123, a gap junction modifier, on prolonged ventricular fibrillation in swine

May 25, 2011·Cardiology·Jing-Sha LiYun Zhang

Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs

Jan 17, 2007·Circulation·Akiko Shiroshita-TakeshitaStanley Nattel

Anti-arrhythmic peptide N-3-(4-hydroxyphenyl)propionyl Pro-Hyp-Gly-Ala-Gly-OH reduces dispersion of action potential duration during ischemia/reperfusion in rabbit hearts

Nov 1, 2002·Journal of Cardiovascular Pharmacology·Anne Louise KjølbyeJørgen Søberg Petersen

Rotigaptide (ZP123) improves atrial conduction slowing in chronic volume overload-induced dilated atria

Jul 27, 2006·Basic & Clinical Pharmacology & Toxicology·Ketil HauganMasamichi Hirose

Pharmacological modulation of gap junction function with the novel compound rotigaptide: a promising new principle for prevention of arrhythmias

Sep 12, 2007·Basic & Clinical Pharmacology & Toxicology·Anne Louise KjølbyeJørgen S Petersen

Short-range intercellular calcium signaling in bone

Nov 11, 2005·APMIS. Supplementum·Niklas Rye Jørgensen

Connexins in Cardiovascular and Neurovascular Health and Disease: Pharmacological Implications

Sep 22, 2017·Pharmacological Reviews·Luc LeybaertRainer Schulz

Pharmacological characterization of the new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2 (ZP123): in vivo and in vitro studies

Jun 28, 2003·The Journal of Pharmacology and Experimental Therapeutics·Anne Louise KjølbyeJorgen Søberg Petersen

Pharmacological modification of gap junction coupling by an antiarrhythmic peptide via protein kinase C activation

Jun 1, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Stephan WengStefan Dhein

The antiarrhythmic peptide analog rotigaptide (ZP123) stimulates gap junction intercellular communication in human osteoblasts and prevents decrease in femoral trabecular bone strength in ovariectomized rats

Aug 20, 2005·Endocrinology·Niklas Rye JørgensenJørgen Søberg Petersen

Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs

Dec 14, 2005·The Journal of Pharmacology and Experimental Therapeutics·James K HennanDavid L Crandall

Increasing gap junction coupling suppresses ibutilide-induced torsades de pointes

Jun 19, 2014·Experimental and Therapeutic Medicine·Lei RuanCuntai Zhang

Discovery of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride (GAP-134)13, an orally active small molecule gap-junction modifier for the treatment of atrial fibrillation

Jan 30, 2009·Journal of Medicinal Chemistry·John A ButeraJørgen S Petersen

Connexins in the Heart: Regulation, Function and Involvement in Cardiac Disease.

May 1, 2021·International Journal of Molecular Sciences·Antonio Rodríguez-SinovasIgnacio Ferreira-González

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Related Papers

Actions of the antiarrhythmic peptide AAP10 on intercellular coupling

(opens in new tab)
Naunyn-Schmiedeberg's Archives of Pharmacology
A MüllerS Dhein
ContactHelpTerms Privacy Cookies
© 2022 Meta ULC. All rights reserved